[Generalized erythema triggered by a rapid decrease of basophils in chronic myeloid leukemia treated with imatinib].
A 57-year-old woman with chronic myeloid leukemia showing severe basophilia (WBC 17.1 X 10(9)/L, basophils 23%) was treated with 400mg imatinib in June 2003. A high basophil count (WBC 10.6 X 10(9)/L, basophils 31%) was still observed after 1 week of therapy. After 9 days of therapy, she developed generalized pruritic skin erythema, chills and high fever. After terminating imatinib treatment, prednisolone therapy was initiated. The rash quickly disappeared. Four days after withdrawal of imatinib, leukocyte count was 13.0 X 10(9)/L with 3% of basophils, suggesting the possibility that rapid decrease in basophils following imatinib therapy may induce severe cutaneous reactions.
Sugito
Motoko
M
First Department Internal Medicine, University of Occupational and Environmental Health, School of Medicine, Kitakyushu.
Tsukada
Junichi
J
Higashi
Takehiro
T
Ohta
Takanori
T
Matsuura
Ai
A
Kubota
Ayumu
A
Mizobe
Takamitsu
T
Mouri
Fumihiko
F
Morimoto
Hiroaki
H
Tanaka
Yoshiya
Y
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001491:Basophils; D001549:Benzamides; D004890:Erythema / Q000209:etiology*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy*; D007964:Leukocytosis / Q000150:complications; D007970:Leukopenia / Q000139:chemically induced* / Q000150:complications; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*; D012720:Severity of Illness Index
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate